CN1509168A - 用于强迫性神经失调(ocd)以及与强迫性神经失调相关疾病使用gvg的新颖治疗方法 - Google Patents

用于强迫性神经失调(ocd)以及与强迫性神经失调相关疾病使用gvg的新颖治疗方法 Download PDF

Info

Publication number
CN1509168A
CN1509168A CNA028098269A CN02809826A CN1509168A CN 1509168 A CN1509168 A CN 1509168A CN A028098269 A CNA028098269 A CN A028098269A CN 02809826 A CN02809826 A CN 02809826A CN 1509168 A CN1509168 A CN 1509168A
Authority
CN
China
Prior art keywords
day
mammal
obsessive
disorder
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028098269A
Other languages
English (en)
Chinese (zh)
Inventor
ʷ�ٷҡ�L������
史蒂芬·L·笛威
D������³��
乔纳森·D·布鲁迪
R
小查尔斯·R·阿西比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Brookhaven Science Associates LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Associates LLC filed Critical Brookhaven Science Associates LLC
Publication of CN1509168A publication Critical patent/CN1509168A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028098269A 2001-05-14 2002-05-08 用于强迫性神经失调(ocd)以及与强迫性神经失调相关疾病使用gvg的新颖治疗方法 Pending CN1509168A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,392 2001-05-14
US09/853,392 US6462084B1 (en) 2001-05-14 2001-05-14 Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG

Publications (1)

Publication Number Publication Date
CN1509168A true CN1509168A (zh) 2004-06-30

Family

ID=25315916

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028098269A Pending CN1509168A (zh) 2001-05-14 2002-05-08 用于强迫性神经失调(ocd)以及与强迫性神经失调相关疾病使用gvg的新颖治疗方法

Country Status (18)

Country Link
US (2) US6462084B1 (enExample)
EP (1) EP1392273A4 (enExample)
JP (1) JP2004533445A (enExample)
KR (1) KR20040028758A (enExample)
CN (1) CN1509168A (enExample)
BR (1) BR0209614A (enExample)
CA (1) CA2446641A1 (enExample)
CZ (1) CZ20033379A3 (enExample)
HR (1) HRP20030894A2 (enExample)
HU (1) HUP0400032A3 (enExample)
IL (1) IL158761A0 (enExample)
MX (1) MXPA03010406A (enExample)
NO (1) NO20035037L (enExample)
NZ (1) NZ529613A (enExample)
PL (1) PL367362A1 (enExample)
TW (1) TWI313599B (enExample)
WO (1) WO2002092071A1 (enExample)
YU (1) YU89103A (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法
CN105431144A (zh) * 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US10512621B2 (en) 2011-12-02 2019-12-24 Synchroneuron, Inc. Methods of treating posttraumatic stress disorder with acamprosate salts

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227052A1 (en) 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
JP2005534678A (ja) * 2002-06-27 2005-11-17 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 注意欠陥多動性障害の治療方法
US7393537B2 (en) 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
WO2004096269A2 (en) * 2003-04-25 2004-11-11 Allergan, Inc. Botulinum neurotoxin for treating tics and obsessive compulsive behaviors
US20110275664A1 (en) * 2005-09-26 2011-11-10 The Regents Of The University Of Colorado,A Body Corporate Method for treating drug and behavioral addictions
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2790820A1 (en) * 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761429A (en) 1985-07-22 1988-08-02 Kenneth Blum Enkephalinase and endorphinase inhibitors as anti-craving compositions
US5189064A (en) 1985-07-22 1993-02-23 Matrix Technologies, Inc. Treatment of cocaine addiction
US4786647A (en) 1986-06-30 1988-11-22 University Of Florida Method for eliciting anxiolysis
US4980168A (en) 1989-10-13 1990-12-25 Natrol, Inc. Dietary supplement for children
EP0767174A1 (de) 1991-11-21 1997-04-09 Ciba-Geigy Ag Neue Aminoalkanphosphinsäuren und ihre Salze
DK0641330T3 (da) * 1992-05-20 2001-12-03 Univ Northwestern Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
EP0915697B1 (en) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US5776956A (en) 1996-07-30 1998-07-07 Lectec Corporation Use of cotinine in treating psychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
IL135659A0 (en) 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
MXPA01004015A (es) * 1998-10-20 2003-03-10 Johnson & Johnson Derivados anticonvulsivos utiles para el tratamiento de la dependencia, adiccion y abuso del alcohol.
MXPA01007758A (es) 1999-02-01 2003-06-24 Johnson & Johnson Uso de derivados de anticonvulsivos para tratar la bulimia nerviosa.
NZ513643A (en) 1999-02-24 2005-04-29 Univ Cincinnati Use of sulfamate derivatives for treating impulse control disorders
AU4050100A (en) 1999-04-08 2000-11-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512621B2 (en) 2011-12-02 2019-12-24 Synchroneuron, Inc. Methods of treating posttraumatic stress disorder with acamprosate salts
CN105431144A (zh) * 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
CN104306736A (zh) * 2014-10-31 2015-01-28 哈尔滨市海江科技开发有限公司 一种治疗疑病症的膏药及其制备方法

Also Published As

Publication number Publication date
CA2446641A1 (en) 2002-11-21
JP2004533445A (ja) 2004-11-04
NO20035037L (no) 2004-01-07
HUP0400032A3 (en) 2012-09-28
PL367362A1 (en) 2005-02-21
HRP20030894A2 (en) 2004-06-30
MXPA03010406A (es) 2004-05-05
WO2002092071A1 (en) 2002-11-21
BR0209614A (pt) 2004-12-07
YU89103A (sh) 2006-08-17
KR20040028758A (ko) 2004-04-03
NZ529613A (en) 2006-09-29
CZ20033379A3 (cs) 2004-12-15
EP1392273A4 (en) 2004-11-24
US20020169103A1 (en) 2002-11-14
HUP0400032A2 (hu) 2004-04-28
IL158761A0 (en) 2004-05-12
EP1392273A1 (en) 2004-03-03
NO20035037D0 (no) 2003-11-13
US6462084B1 (en) 2002-10-08
TWI313599B (en) 2009-08-21

Similar Documents

Publication Publication Date Title
AU2025204612A1 (en) MDMA enantiomers
PT1187603E (pt) ''terapia de associação para promover a perda de peso e o tratamento da obesidade''
CN1138539C (zh) 用于降低神经酰胺水平的碱性氨基酸和衍生物的应用
JP5409602B2 (ja) 慢性疼痛の治療におけるジミラセタムの使用
US12220389B2 (en) Combination therapy for the treatment of tinnitus and other medical conditions
RU2020125170A (ru) Композиции и способы улучшения биодоступности 5-гидрокситриптофана
US6462084B1 (en) Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
CN104013638B (zh) 当药黄素及其衍生物的用途
BOSHES Sinemet and the treatment of parkinsonism
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
JPS60252416A (ja) Ｃｄｐコリン組成物
CN105832724B (zh) 吲哚醇在制备抗抑郁症药物中的用途
US6011054A (en) Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin
CN116712420B (zh) 一种花椒酰胺在制备治疗多发性硬化症的药物中的应用
AU2002259153B2 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
US20250325500A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction
EP3713556A1 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
CN113015524A (zh) 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
JP2009073744A (ja) 片頭痛の予防治療剤
TW200526197A (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
EP4199723A1 (en) Methods of treating fibromyalgia with neuroactive steroids
AU2002259153A1 (en) Novel treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
JP2008506630A (ja) ゾルピデムの更なる治療的使用
TCA Antidepressants and Anticonvulsants
CA3160623A1 (fr) Utilisation de composes pour la prevention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication